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Vaccination is one of the most powerful tools to extend the 
average lifespan of humans. Vaccination has successfully 
eradicated smallpox and significantly reduced the morbidity 
and mortality of several infectious diseases, such as polio-
myelitis [1]. It is currently one of the most effective 
measures to control infectious diseases [1]. The health ben-
efits brought by widespread vaccination are beyond doubt, 
whether for public health or individuals.  
However, the development of vaccination has also been 
accompanied by tragedy. In the late 19th century, the rabies 
vaccine that was produced by nerve tissue cells prevented a 
large number of deaths, but epilepsy, paralysis and/or coma 
appeared in one of every 230 persons vaccinated [2]. In 
1942, hundreds of thousands of American soldiers were 
vaccinated with the yellow fever vaccine, which contained 
human serum. Some of the serum was from hepatitis B vi-
rus carriers, and 330000 soldiers were infected; 50000 de-
veloped with acute hepatitis and 62 died [3]. In 1955, an 
American company produced the inactivated polio vaccine, 
but the inactivation was not sufficient. Among the 120000 
children who were vaccinated with this lot of vaccine, there 
were 40000 cases of mild poliomyelitis, 200 cases of per-
manent paralysis, and 10 deaths [4].  
No medical intervention is absolutely safe. Even if a 
population with the required health status receives a vaccine 
of reliable quality according to the normal procedures, rare 
but serious adverse reactions may occur. For example, the 
attenuated oral polio vaccine can cause paralytic poliomye-
litis [5]; the whole-cell pertussis vaccine can cause acute 
encephalitis [6]; the rubella vaccine can cause acute arthritis 
[7]; some influenza vaccines can cause Guillain-Barre syn-
drome [8]; and the measles, mumps and rubella (MMR) 
vaccine containing gelatin can cause severe allergic reac-
tions [9].  
The target of vaccination is a healthy population. While 
the tolerance of healthy people for adverse events after vac-
cination is significantly lower than that of the patients who 
need other medical intervention measures such as drugs and 
surgery. Therefore, the safety standards of vaccines are sig-
nificantly higher than those of other medical intervention 
measures. The safety monitoring of vaccines begins at the 
pre-clinical development phase, and continues through reg-
istered clinical trials and after the product is brought to the 
market. Before a vaccine enters clinical trials, its safety 
must be verified in various animal models. If the vaccine 
may be used for women of childbearing age, the safety veri-
fication must include sufficient assessment during pregnan-
cy and any impact on embryonic growth and development 
must also be assessed. In phase I–III clinical trials, vaccine 
safety and efficacy is usually assessed gradually in thou-
sands, to tens of thousands, and >100000 volunteers. In 
phase II/III trials, usually a randomized controlled dou-
ble-blind design is used, with volunteers randomly assigned 
to test and control groups. The test group is treated with 
vaccine, while the control group receives a placebo (blank 
adjuvant or irrelevant vaccine). Safety assessment includes 
observation of local reactions (such as pain, redness, swell-
ing and induration) and systemic reactions (such as fever, 
allergic skin rash, fatigue, weakness and headache) within 
30 days post vaccination. Safety assessment also includes 
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the incidence and correlation with vaccination of all serious 
adverse events (such as hospitalization, death, permanent 
disability, and fetal malformation) throughout the clinical 
trial (usually 1–3 years). Usually the time relevance, bio-
logical plausibility, association specificity, strength of asso-
ciation, consistency of association, and other principles 
need to be considered when determining the correlation 
between vaccines and adverse events, which is a complex 
process.  
Vaccine related serious adverse reactions are usually rare, 
occurred delayed, some particular subgroups may have 
higher risk of adverse reactions, and it is not possible to 
expand the clinical trial sample size indefinitely, thus they 
are difficult to be detected. Historically, the assessment of 
rare adverse reactions mainly depended on the establish-
ment of a passive adverse event reporting system after the 
vaccine came on the market, and on some targeted epidemi-
ological studies. Recently, more countries have established 
routine reporting systems for adverse events in phase IV 
clinical trials after the vaccine has come to market. These 
measures significantly improve our ability to detect serious 
vaccine adverse reactions, as well as any defects in the vac-
cine lot or its manufacture. However, some systemic defects 
that cannot be overcome still exist in this system. For ex-
ample, the baseline incidence of some serious adverse 
events is unknown, and the baseline disease risk differs ac-
cording to the socioeconomic status of the vaccinated and 
unvaccinated populations. These differences make it diffi-
cult to judge whether the vaccinated population really has a 
higher risk of adverse events. 
Usually, the national vaccine administrator will decide 
on how the vaccine should be used after scientific assess-
ment of the adverse reactions after vaccination. The existing 
rotavirus vaccine on the European and American markets 
may cause infant intussusception after the first dose, with an 
incidence of about one to two per hundred thousand. How-
ever, compared with hospitalization and death caused by 
vaccine-preventable rotavirus infection, the benefits out-
weigh the risks, thus, these two vaccines are still in use [10]. 
Domestic and international experience show that (Figure 
1) along with the increased rate of vaccination, most people 
have developed protective antibodies; susceptible popula-
tions have been reduced; and the spread of pathogenic mi-
croorganisms has become difficult, which resulted in a rapid 
decline in disease incidence. Because the relevant diseases 
are on the wane and vaccine adverse events start to gain 
more attention, then the willingness to receive vaccination 
is decreasing. This is resulting in a resurgence of the dis-
eases and their incidence, much more people suffered from 
the disease. Having experienced the painful lessons, people 
have started to receive vaccination again and the vaccina-
tion rate has gradually recovered. If vaccination rates could 
be maintained for a certain period, the diseases in question 
could be eliminated. As a result, people would no longer 
need vaccination, and any adverse events caused by the 
disease or vaccination would be eliminated at the same 
time. 
Several large-scale campaigns to boycott vaccines have 
occurred but they have all ended with resumption of vac-
cination at the expense of suffering from the epidemic dis-
eases. From the 1970s to 1980s, extensive vaccination with 
whole-cell pertussis reduced the incidence of pertussis to 
below 1/100000, which resulted in doubt about the need for 
vaccination [11]. A report that 36 infants developed neuro-
logical symptoms after vaccination dented expert and public 
confidence in the vaccine in the UK, and the vaccination 
rate decreased from 81% to 31% [11]. This resulted in an 
increase in the incidence of pertussis to >100/100000, 
with >100000 cases and 36 deaths. To gain people’s confi-
dence, the British government took active measures to 
re-evaluate the effect of vaccination. The incidence of per-
tussis returned to its previous low level after the vaccination 
rate increased to 93% [11,12]. At the same time, Japan 
changed the diphtheria, tetanus and pertussis vaccine into 
the diphtheria and tetanus vaccine for the same reason. Af-
ter two infants died as a result of vaccination with 
whole-cell pertussis in Japan, and the Ministry of Health 
stopped pertussis vaccination of infants. Consequently, the 
vaccination rate decreased from 80% in 1974 to 10% in 
1976. In 1979, >13000 cases of pertussis appeared and 41 
people died [11]. In the UK, measles vaccine is another 
controversial issue. In 1998, Wakefield et al. published 
journal paper in The Lancet, which claimed a connection 
between MMR vaccination and autism in children [13]. As 
a result of media publicity, MMR vaccination rate de-
creased from 92% in 1995–1996 to 80% in 2003–2004 [14]. 
Since 1999, the UK has experienced a continuous outbreak 
of measles [15]. In the meantime, the scientific community 
carried out a lot of research to verify the connection be-
tween the MMR vaccine and autism in children. In 2003, 
sufficient scientific data proved that MMR vaccine has no 
connection with autism in children [16,17]. After that, the 
MMR vaccination rate rose gradually, reaching 90% in 
2010; its highest for nearly 13 years. However, this is still 
lower than 95% measles vaccination rate recommended by 
the World Health Organization. In 2010, Wakefield’s paper 
was revoked by The Lancet. 
Hepatitis B vaccine is a mature agent. In China, the use 
of hepatitis B vaccine began in 1986 and it was included in 
the childhood immunization program in 1992. As a result, 
China has made great progress in controlling hepatitis B 
virus (HBV) infection. From 1992 to 2006, the seropreva-
lence of hepatitis B surface antigen (HBsAg) in people aged 
1–59 years decreased from 9.75% to 7.20% [18]. There was 
also a reduction of 16–20 million HBsAg carriers and 
2.8–3.5 million deaths from HBV infection. In those aged 
<5 years, the HBsAg positivity was only 1.0%, a decrease 
of 90%. Newborn infants and infants have received hepatitis 
B vaccination worldwide, which has proved the safety of 
the vaccine. It has been reported that hepatitis B vaccine 
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Figure 1  Promotion of vaccination programs and changes in disease (modified from [1]). A, Before vaccination. B, Coverage rate significantly increased 
after vaccine appeared on the market. C, Period of fluctuation in public willingness for vaccination. D, Vaccination willingness recovery period. E, Patho-
gens and relevant disease elimination period.  
may be related to multiple sclerosis (MS) and other auto-
immune diseases in overseas countries. American and Eu-
ropean researchers have conducted a case-control study [19] 
and a retrospective analysis of MS cases in a European da-
tabase [20]. They have found that hepatitis B vaccine does 
not increase the risk of multiple sclerosis. In China, the 
public health emergency events surveillance system from 
January 2006 to March 2007 showed that there were 10 
deaths after hepatitis B vaccination. In two cases, it could 
not be ruled out acute anaphylactic shock after vaccination, 
and in the remaining eight cases, the primary causes of 
death had nothing to do with hepatitis B vaccine. According 
to the historical data, the safety and effectiveness of hepati-
tis B vaccine are beyond doubt. 
Recently, many areas of China have reported deaths after 
hepatitis B vaccination, which have raised media concern. 
Were these deaths a coincidence, or were they caused by 
quality problems with certain lots of vaccines or some man-
ufacturers, or the hepatitis B vaccine itself? We are pres-
ently awaiting the results of further investigation. Combined 
with the earlier polio vaccine adverse events, which have 
attracted extensive societal concern, we should pay special 
attention, be vigilant about the resurgence of anti-vaccine 
campaigns, and avoid repeating in China the historical mis-
takes in other countries. Most cases of chronic hepatitis B in 
China are caused by mother-to-child transmission or child-
hood infection. If the Chinese neonatal hepatitis B vaccina-
tion rate decreased from 90% to 70%, it would mean that 
3.2 million among 16 million neonates would face the risk 
of HBV infection each year. When calculated in accordance 
with the HBsAg seroprevalence of Chinese women of 
childbearing age (7%), the perinatal transmission rate of the 
HBsAg-positive mothers (40%) and hepatitis B vaccine 
protection rate of newborns born to HBsAg-positive moth-
ers (90%), another 40000 newborns (160000007%40% 
90%10%=40000) will be infected each year if vaccination 
rate falls by 10%. Among the 40000 infected newborn in-
fants, 90% (36000) will develop chronic infection and 25% 
(10000) chronic liver disease (including cirrhosis and hepa-
tocellular carcinoma). Therefore, we should rationally re-
spond to vaccine adverse events, actively establish the cor-
relation and causes of adverse events, and take appropriate 
response measures to minimize the damage. 
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